Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Extension to the Phase 2 Randomized, Double-blind, Placebo-controlled, Crossover Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients With Active Polymyositis or Dermatomyositis

NCT04628936 is registered in ClinicalTrials.gov with Kezar Life Sciences, Inc. as lead sponsor.

NCT NCT04628936
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04628936 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Extension to the Phase 2 Randomized, Double-blind, Placebo-controlled, Crossover Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients With Active Polymyositis or Dermatomyositis
Lead sponsor
Kezar Life Sciences, Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 4, 2020
Completion date
June 12, 2023
Enrollment
18 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

dermatomyositis, polymyositis